Tag: Plasma kallikrein inhibitor

Hereditary angioedema (HAE) is a rare genetic condition that affects an estimated 1 in 50,000 people globally. For those managing this condition, understanding their medication is crucial, which is why many ask: **What is the generic name for Orladeyo?** The answer is berotralstat.

In clinical trials, adults and adolescents taking Orladeyo once daily experienced a significant reduction in hereditary angioedema (HAE) attacks, with one study showing a 91% reduction over two years compared to pre-treatment rates. For many patients, understanding **how effective is Orladeyo** involves reviewing clinical evidence and considering its convenience as the first oral prophylactic HAE treatment.

Hereditary angioedema (HAE) affects an estimated 6,000 people in the United States, and the treatment landscape has expanded significantly with the approval of oral medications. The answer to "What is the pill for hereditary angioedema?" depends on the purpose of the medication: prevention of attacks versus on-demand treatment.

In clinical trials, the Orladeyo treatment demonstrated a significant reduction in the rate of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older. As the first oral medication for HAE prophylaxis, it offers a convenient and effective option for managing this rare genetic disorder.